RU2016124871A - Композиции бендамустина и циклополисахарида - Google Patents
Композиции бендамустина и циклополисахарида Download PDFInfo
- Publication number
- RU2016124871A RU2016124871A RU2016124871A RU2016124871A RU2016124871A RU 2016124871 A RU2016124871 A RU 2016124871A RU 2016124871 A RU2016124871 A RU 2016124871A RU 2016124871 A RU2016124871 A RU 2016124871A RU 2016124871 A RU2016124871 A RU 2016124871A
- Authority
- RU
- Russia
- Prior art keywords
- cyclopolysaccharide
- beta
- cyclodextrin
- composition according
- bendamustine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 7
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical group ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims 3
- 229960002707 bendamustine Drugs 0.000 title claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (6)
1. Композиция, включающая бендамустин и заряженный циклополисахарид, причем заряженный циклополисахарид имеет одну или более анионных групп, которые выбирают из группы, включающей сульфатные или сульфонильные группы, и указанный циклополисахарид является бета-циклодекстрином.
2. Композиция по п. 1, отличающаяся тем, что циклополисахарид представляет собой сульфобутиловый эфир бета-циклодекстрина, сульфопропилированный бета-цикл одекстрин или О-сульфатированный бета-циклодекстрин.
3. Композиция по п. 2, отличающаяся тем, что циклополисахарид представляет собой сульфобутиловый эфир бета-циклодекстрина.
4. Композиция по п. 1, отличающаяся тем, что соотношение бендамустина к циклополисахариду по весу составляет, приблизительно, от 1:12500 до, приблизительно, 1:25.
5. Композиция по п. 1, отличающаяся тем, что дополнительно содержит маннитол.
6. Композиция по п. 1, отличающаяся тем, что бета-циклодекстрин представляет собой натриевый бета-циклодекстрин.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20854109P | 2009-02-25 | 2009-02-25 | |
| US61/208,541 | 2009-02-25 | ||
| US26994409P | 2009-07-01 | 2009-07-01 | |
| US61/269,944 | 2009-07-01 | ||
| US27136409P | 2009-07-20 | 2009-07-20 | |
| US61/271,364 | 2009-07-20 | ||
| US27929309P | 2009-10-19 | 2009-10-19 | |
| US61/279,293 | 2009-10-19 | ||
| US12/711,979 | 2010-02-24 | ||
| US12/711,979 US8436032B2 (en) | 2009-02-25 | 2010-02-24 | Bendamustine cyclopolysaccharide compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011138844/15A Division RU2591804C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016124871A true RU2016124871A (ru) | 2018-12-04 |
| RU2016124871A3 RU2016124871A3 (ru) | 2019-11-11 |
| RU2734236C2 RU2734236C2 (ru) | 2020-10-13 |
Family
ID=42631521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016124871A RU2734236C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
| RU2011138844/15A RU2591804C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011138844/15A RU2591804C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8436032B2 (ru) |
| EP (2) | EP2792369B1 (ru) |
| JP (1) | JP5654498B2 (ru) |
| KR (1) | KR101798951B1 (ru) |
| CN (2) | CN102935080A (ru) |
| AU (1) | AU2010217297A1 (ru) |
| CA (1) | CA2753641C (ru) |
| ES (2) | ES2675620T3 (ru) |
| HU (1) | HUE038234T2 (ru) |
| NO (1) | NO2792369T3 (ru) |
| RU (2) | RU2734236C2 (ru) |
| WO (1) | WO2010097700A1 (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| PT2528602T (pt) | 2010-01-28 | 2017-01-12 | Eagle Pharmaceuticals Inc | Formulações de bendamustina |
| WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| US20110207764A1 (en) * | 2010-02-23 | 2011-08-25 | Valery Alakhov | Cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| PT2758052T (pt) * | 2011-09-18 | 2018-03-29 | Euro Celtique Sa | Composição farmacêutica que compreende um inibidor de hdac e um ciclopolissacárido |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| EP4360621A3 (en) * | 2012-03-20 | 2024-05-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| ES2943668T3 (es) | 2012-03-20 | 2023-06-15 | Eagle Pharmaceuticals Inc | Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración |
| JP2016501876A (ja) * | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| US9849115B2 (en) * | 2013-08-27 | 2017-12-26 | Vasilios Voudouris | Bendamustine pharmaceutical compositions |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| MX2020003511A (es) | 2017-10-05 | 2020-07-22 | Tube Pharmaceuticals Gmbh | Formulaciones orales de bendamustina. |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP2022522928A (ja) | 2018-12-18 | 2022-04-21 | ムンディファーマ・インターナショナル・コーポレーション・リミテッド | 多発性骨髄腫を治療するための化合物 |
| JP2023529033A (ja) * | 2020-04-09 | 2023-07-07 | ビカ・バイオテック（グアンジョウ）・カンパニー・リミテッド | ベンダムスチン組成物及びその用途 |
| CN111557904A (zh) * | 2020-04-09 | 2020-08-21 | 比卡生物科技（广州）有限公司 | 苯达莫司汀组合物及其用途 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5068226A (en) * | 1987-12-07 | 1991-11-26 | Cyclex, Inc. | Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| DE59607089D1 (de) * | 1995-03-10 | 2001-07-19 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
| JP4979843B2 (ja) * | 1995-03-10 | 2012-07-18 | ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 微粒子の形のポリペプチド含有投薬形 |
| US6624141B1 (en) * | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| CN1646171B (zh) * | 2002-04-19 | 2010-05-26 | 诺瓦提斯公司 | 新型生物材料、其制备和用途 |
| CA2512052C (en) * | 2002-12-31 | 2016-06-21 | Altus Pharmaceuticals Inc. | Human growth hormone crystals and methods for preparing them |
| AU2004311478A1 (en) * | 2003-12-31 | 2005-07-21 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| WO2005094830A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| WO2005120551A1 (en) * | 2004-06-07 | 2005-12-22 | Nastech Pharmaceutical Company Inc. | Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides |
| CA2574555A1 (en) * | 2004-08-03 | 2006-02-09 | Royal College Of Surgeons In Ireland | Phenytoin formulations, and uses thereof in wound healing |
| JP2008519032A (ja) * | 2004-11-03 | 2008-06-05 | キュラジェン コーポレイション | Ｆｇｆ−２０の調合物、生成方法および使用 |
| TW200621240A (en) * | 2004-11-05 | 2006-07-01 | Salmedix Inc | Cancer treatments |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
| AU2006211485B2 (en) * | 2005-01-28 | 2011-04-14 | Brigham Young University | Bacterial glycolipid activation of CD1d-restricted NKT cells |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN1846685A (zh) | 2006-01-25 | 2006-10-18 | 济南帅华医药科技有限公司 | 含苯达莫司汀和其增效剂的缓释注射剂 |
| CN101646419A (zh) | 2006-11-08 | 2010-02-10 | 诺瓦瓦克斯股份有限公司 | 制备多相药物组合物的固体剂型的方法 |
| US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| WO2008106721A1 (en) * | 2007-03-02 | 2008-09-12 | University Of Wollongong | Compositions and methods for delivery of anti-cancer agents |
| CN101219113A (zh) | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| CN101606934B (zh) * | 2009-07-27 | 2011-09-28 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀组合物 |
-
2010
- 2010-02-24 AU AU2010217297A patent/AU2010217297A1/en not_active Abandoned
- 2010-02-24 JP JP2011550669A patent/JP5654498B2/ja active Active
- 2010-02-24 CA CA2753641A patent/CA2753641C/en active Active
- 2010-02-24 KR KR1020117022330A patent/KR101798951B1/ko active Active
- 2010-02-24 WO PCT/IB2010/000502 patent/WO2010097700A1/en not_active Ceased
- 2010-02-24 NO NO14177306A patent/NO2792369T3/no unknown
- 2010-02-24 EP EP14177306.9A patent/EP2792369B1/en active Active
- 2010-02-24 HU HUE14177306A patent/HUE038234T2/hu unknown
- 2010-02-24 RU RU2016124871A patent/RU2734236C2/ru not_active Application Discontinuation
- 2010-02-24 ES ES14177306.9T patent/ES2675620T3/es active Active
- 2010-02-24 US US12/711,979 patent/US8436032B2/en active Active
- 2010-02-24 EP EP10745872.1A patent/EP2400987B1/en active Active
- 2010-02-24 CN CN2012104076231A patent/CN102935080A/zh active Pending
- 2010-02-24 ES ES10745872.1T patent/ES2525257T3/es active Active
- 2010-02-24 CN CN2010800183017A patent/CN102421451B/zh active Active
- 2010-02-24 RU RU2011138844/15A patent/RU2591804C2/ru not_active Application Discontinuation
-
2013
- 2013-03-11 US US13/793,442 patent/US8703964B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120015294A (ko) | 2012-02-21 |
| RU2591804C2 (ru) | 2016-07-20 |
| JP2012519657A (ja) | 2012-08-30 |
| NO2792369T3 (ru) | 2018-09-15 |
| US8436032B2 (en) | 2013-05-07 |
| JP5654498B2 (ja) | 2015-01-14 |
| ES2675620T3 (es) | 2018-07-11 |
| EP2792369A1 (en) | 2014-10-22 |
| US20100216858A1 (en) | 2010-08-26 |
| EP2400987A1 (en) | 2012-01-04 |
| EP2400987B1 (en) | 2014-09-03 |
| CN102935080A (zh) | 2013-02-20 |
| AU2010217297A1 (en) | 2011-10-20 |
| CA2753641A1 (en) | 2010-09-02 |
| WO2010097700A1 (en) | 2010-09-02 |
| ES2525257T3 (es) | 2014-12-19 |
| CN102421451B (zh) | 2013-11-06 |
| CA2753641C (en) | 2014-09-16 |
| US20130190372A1 (en) | 2013-07-25 |
| KR101798951B1 (ko) | 2017-11-20 |
| EP2400987A4 (en) | 2012-08-22 |
| CN102421451A (zh) | 2012-04-18 |
| EP2792369B1 (en) | 2018-04-18 |
| US8703964B2 (en) | 2014-04-22 |
| RU2011138844A (ru) | 2013-04-10 |
| RU2016124871A3 (ru) | 2019-11-11 |
| RU2734236C2 (ru) | 2020-10-13 |
| HUE038234T2 (hu) | 2018-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016124871A (ru) | Композиции бендамустина и циклополисахарида | |
| MX345025B (es) | Producto detergente. | |
| EP2314274A3 (en) | Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener | |
| MY157314A (en) | Oral compositions and uses thereof | |
| MX2010010236A (es) | Acidos sulfoperoxicarboxilicos, su preparacion y metodos de uso como agentes blanqueadores y antimicrobianos. | |
| MX2012003388A (es) | Acidos sulfoperoxicarboxilicos, su preparacion y metodos de uso como agentes blanqueadores y antimicrobianos. | |
| TW200635938A (en) | Fluorosurfactants | |
| NZ596254A (en) | Cleanser compositions and methods for using the same comprising linalool, hinokitiol, diol and surfactant | |
| EA201390665A1 (ru) | Несмываемые нетвердые кондиционирующие композиции для кожи, содержащие 12-гидроксистеариновую кислоту | |
| RU2012134318A (ru) | Стабилизация пленки оксида цинка в композициях для ухода за полостью рта | |
| WO2011069629A3 (en) | Pharmaceutical composition comprising oligopeptides, preferably cilengitide | |
| PL2004807T3 (pl) | Kompozycje do wytwarzania dojrzałych komórek dendrytycznych | |
| AR074270A1 (es) | Composicion de champu concentrada | |
| EA201491022A1 (ru) | Туалетное мыло с улучшенной пенообразующей способностью | |
| BR112013013117A2 (pt) | agente hidrotrópico, uso do mesmo para tornar solúveis tensoativos não iônicos e composições contendo os mesmos | |
| AR074271A1 (es) | Composicion de champu concentrada | |
| CR10371A (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6 | |
| JP2015523303A5 (ru) | ||
| RU2014128838A (ru) | Солюбилизированные аналоги магнолола | |
| JP2009263291A5 (ru) | ||
| EP2314275A3 (en) | Compositions comprising a low-dp polymerized surfactant and a micellar thickener | |
| BR112012005667A2 (pt) | '' agente fluorescente particulado topoespec´fico, composição detergente, composição cosmética, processos de preparação de um agente fluorescente particulado bipolar, uso de uma particula de argila de uso de um agente fluorescente particulado'' | |
| FR2919999B1 (fr) | Compositions d'acide hyaluronique | |
| RU2008110880A (ru) | Композиционный состав для укрепления грунта | |
| Li et al. | Two integrable couplings of the Tu hierarchy and their Hamiltonian structures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190624 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20190813 |